查看文章

In this report, we have set out to provide a comprehensive landscape analysis of MS in Australia, and how that landscape has changed since 2010. The report aimed to provide an up to date prevalence of MS in Australia for 2017, estimate the costs of MS in Australia from an individual and societal perspective, and assess the impact of MS on QoL using the latest available data and updated methodologies.

Using a previously published method of estimating Australian prevalence of MS using data from the Pharmaceutical Benefits Scheme on prescriptions of MS disease modifying therapies (DMTs), that takes in to account the proportion of people with MS who use DMTs, we found that the number of people in Australia afected by MS in December 2017 was 25,607 (95% confidence interval [CI]: 24,874− 26,478).